Intet tydede på, at infektionshyppigheden i samtlige PNH - undersøgelser under ét var forhøjet i forhold til placebo, heller ikke alvorlige infektioner, svære infektioner eller multiple infektioner.
There was no evidence of an increased incidence of infection across PNH studies with eculizumab as compared to placebo, including serious infections, severe infections or multiple infections.